Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis

Página do item simplificado
dc.contributor.authorTheodoro, Therese Rachell
dc.contributor.authorMatos, Leandro Luongo de [UNIFESP]
dc.contributor.authorSant'Anna, Aleksandra Vanessa Lambiasi
dc.contributor.authorFonseca, Fernando Luiz Affonso [UNIFESP]
dc.contributor.authorSemedo, Patricia [UNIFESP]
dc.contributor.authorMartins, Lourdes Conceicao
dc.contributor.authorNader, Helena Bonciani [UNIFESP]
dc.contributor.authorDel Giglio, Auro
dc.contributor.authorPinhal, Maria Aparecida da Silva [UNIFESP]
dc.contributor.institutionFac Med ABC
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T13:48:45Z
dc.date.available2016-01-24T13:48:45Z
dc.date.issued2007-06-01
dc.description.abstractHeparanase is an endo-beta-glucuronidase that is capable of degrading heparan sulfate chains of proteoglycans, generating a variety of bioactive molecules such as growth factors and chemotactic and angiogenic agents. the expression of heparanase was investigated in the peripheral blood mononuclear cell fraction ( PBMC) of 30 patients with breast cancer and 20 healthy control women by reverse transcription-polymerase chain reaction ( RT-PCR) and immunocytochemistry. PBMC samples from all breast cancer patients at study entry showed the expression of heparanase, whereas no expression was observed for healthy women. Immunocytochemistry analysis demonstrated that heparanase was expressed in lymphocytes of breast cancer PBMC. Throughout follow-up, heparanase expression by RTPCR decreased significantly after surgery in patients treated with neoadjuvant chemotherapy ( P = .002) and after tamoxifen treatment ( P = .040), whereas it increased significantly with the advent of systemic metastasis ( P = .027). in vitro, either serum from breast cancer patients or a medium originated from co-culture experiments of MCF-7 cells and lymphocytes from healthy women stimulated heparanase expression in normal lymphocytes. the results suggest that there is a tumor-inducing effect on heparanase expression by lymphocytes present in the PBMCs of breast cancer patients, which depends, in turn, on the interaction between a tumor and normal lymphocytes.en
dc.description.affiliationFac Med ABC, Dept Bioquim, São Paulo, Brazil
dc.description.affiliationFac Med ABC, Dept Oncol, São Paulo, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Bioquim, São Paulo, Brazil
dc.description.affiliationFac Med ABC, Dept Saude Comunitaria, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Bioquim, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent504-510
dc.identifierhttp://dx.doi.org/10.1593/neo.07241
dc.identifier.citationNeoplasia. Ann Arbor: Neoplasia Press, v. 9, n. 6, p. 504-510, 2007.
dc.identifier.doi10.1593/neo.07241
dc.identifier.issn1522-8002
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/29779
dc.identifier.wosWOS:000247366800007
dc.language.isoeng
dc.publisherNeoplasia Press
dc.relation.ispartofNeoplasia
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectheparanaseen
dc.subjectbreast canceren
dc.subjectlymphocytesen
dc.subjecttumor markersen
dc.subjectmetastasisen
dc.titleHeparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasisen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos